Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease
Abstract
The pathological process of neurodegeneration, which is observed in Alzheimer's (AD) and Parkinson's (PD) diseases and that follows any insult to the central nervous system, is accompanied by an inflammatory reaction, which is believed to contribute to the pathogenesis of the diseases. In accordance to this, the anti-inflammatory agents are suggested to be effective in slowing or inhibiting the degenerative process. In this study, we investigated the influence of dexamethasone (DXM) on the nigrostriatal dopaminergic neurons damage following administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropiridine (MPTP). Mice C57BL received pre-treatment of the various doses of dexamethasone followed by MPTP administration (40 mg/kg). We found that dexamethasone 1 mg/kg diminished a dopamine content depletion in striatum by about 20%, when the doses of 0.1 mg/kg was ineffective and 10 mg/kg even aggravate the dopamine content decrease. In the second step of the experiment, we chose the effective doses, 1 mg/kg, and started the treatment before and 24 h after MPTP administration. We observed the same protection in both situations: less dopamine depletion and less decrease in the number of dopaminergic cells in the substantia nigra (SN). Dexamethasone also similarly decreased the inflammatory reaction (glial activation, lymphocytic infiltration) in the injured areas. Our study showed that dexamethasone may exert a neuroprotective effect towards neurons injured by MPTP, but only when used in a proper dose. The mechanism of dexamethasone protective properties may be an inhibition of inflammatory process; however, direct interactions with neurons are also possible.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Alternative anti-inflammatory drugs including dexamethasone, minocycline, naloxone are being or have been tested in preclinical and clinical trials for PD.
“Alternative drugs with anti-inflammatory properties, including dexamethasone, minocycline, naloxone, are going to be or have already been tested in preclinical and clinical trials.560–562”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [561]
Cites
Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
in 't Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M. B., & Stricker, B. H. C. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010178 · Cited by 1,196 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Role of neuroinflammation in neurodegeneration development
Zhang, W., Xiao, D., Mao, Q., & Xia, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01486-5 · Cited by 1,668 · see citing works
Tansey, M. G., & Goldberg, M. S. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.11.004 · Cited by 1,045 · see citing works
Neuroinflammation in Parkinson's disease and its potential as therapeutic target
Wang, Q., Liu, Y., & Zhou, J. (2015) · Translational Neurodegeneration · doi:10.1186/s40035-015-0042-0 · Cited by 884 · see citing works
Koprich, J. B., Reske-Nielsen, C., Mithal, P., & Isacson, O. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-8 · Cited by 355 · see citing works
Rogers, J., Mastroeni, D., Leonard, B., Joyce, J., & Grover, A. (2007) · International Review of Neurobiology · doi:10.1016/s0074-7742(07)82012-5 · Cited by 260 · see citing works
Inflammation in Parkinson’s disease: role of glucocorticoids
Herrero, M.-T., Estrada, C., Maatouk, L., & Vyas, S. (2015) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2015.00032 · Cited by 175 · see citing works
“…GC agonists e.g., corticosterone that artificially increase GCs above endogenous levels, conversely adrenalectomy augments dopamine neuronal loss (Kurkowska-Jastrzebska et al., 2004; Sugama et al., 2009; Ros-Bernal et al., 2011) indicating that high levels of GCs present during MPTP intoxication…”
BackgroundTentillier, N., Etzerodt, A., Olesen, M. N., Rizalar, F. S., Jacobsen, J., Bender, D., Moestrup, S. K., & Romero-Ramos, M. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.1636-16.2016 · Cited by 109 · see citing works
Molecular and cellular immune mediators of neuroprotection
Turrin, N. P., & Rivest, S. (2006) · Molecular Neurobiology · doi:10.1385/mn:34:3:221 · Cited by 85 · see citing works
Role of glucocorticoids in dopamine-related neuropsychiatric disorders
Craenenbroeck, K. V., Bosscher, K. D., Berghe, W. V., Vanhoenacker, P., & Haegeman, G. (2005) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2005.10.007 · Cited by 64 · see citing works
- Authors
- Kurkowska-Jastrzębska, I., Litwin, T., Joniec, I., Ciesielska, A., Przybyłkowski, A., Członkowski, A., & Członkowska, A.
- Affiliations
- Institute of Psychiatry and Neurology (PL)
- Corresponding author
- Członkowska, Anna
- Venue
- International Immunopharmacology
- Publisher
- Elsevier BV
- Published
- 2004-10
- Volume
- 4
- Issue
- 10-11
- Pages
- 1307-1318
- ISSN
- 1567-5769 (ISSN-L)
- OpenAlex
- W2059884588
- Cited by
- 117
- References
- 1
- Citations by year
- 2025: 3 · 2024: 5 · 2023: 5 · 2022: 4 · 2021: 4 · 2020: 8 · 2019: 6 · 2018: 4 · 2017: 10 · 2016: 2 · 2015: 8 · 2014: 4 · 2013: 5 · 2012: 8
- FWCI
- 3.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Immunopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nuclear Receptors and Signaling
- Keywords
- dexamethasone, Parkinson's disease, MPTP, neuroprotection, dopaminergic neurons, substantia nigra, striatum, dopamine depletion, neuroinflammation, glial activation, lymphocyte infiltration, dose-dependent effects
- MeSH terms
- Animals, Anti-Inflammatory Agents, Chromatography, High Pressure Liquid, Corpus Striatum, Dexamethasone, Disease Models, Animal, Dopamine, Dose-Response Relationship, Drug, Inflammation, Male, Mice, Inbred C57BL, Nerve Degeneration, Neurons, Parkinson Disease, Secondary, Blotting, Western, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Neuroprotective Agents, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review